The ChimeriVax vaccine, produced by international vaccine research and production company Sanofi Pasteur, will undergo a six-year trial to test its seroconversion rate (ability to produce antibodies) against four dengue virus serotypes.
The safety of the drug will also be evaluated during the trial.
The Pasteur Institute of Ho Chi Minh City will conduct the trial on 180 healthy people of different ages in the province through 2014.
Sanofi Pasteur, the vaccine division of the France-based Sanofi-Aventis Group, has already completed two trial phases of the tetravalent vaccine.
The latest test results were presented last September with a 100 percent seroconversion rate reported for all four dengue serotypes.
The third trial phase was launched this year in Latin America and Asia.
More than 28,890 dengue fever cases have been reported in Vietnam this year, including 28 that have ended in death, according to the Ministry of Health.
Reported by Nam Son |
E-mail to a friend 
Print version
To top
